Utility of TaqMan Array Cards for detection of acute febrile illness etiologies in patients suspected of viral hemorrhagic fever infections

TaqMan 阵列卡在疑似病毒性出血热感染患者急性发热性疾病病因检测中的应用

阅读:2

Abstract

INTRODUCTION: Due to the difficulty in attributing a causative agent to acute febrile illnesses (AFI), multi-pathogen diagnostic tools should be prioritized in low-resource settings. A previously developed AFI-TaqMan Array Card (AFI-TAC), capable of detecting 26 pathogens within 2 h of nucleic acid extraction, was evaluated in Uganda. METHODS: A cross-sectional retrospective study design was employed and utilized 182 viral hemorrhagic fever (VHF)-negative samples collected from Uganda, DRC, South Sudan and Kenya during routine surveillance from August 2018- March, 2019. These samples were tested on AFI-TAC targeting 17 viral, 8 bacterial and 3 protozoal pathogens known to cause fever. Patients with a body temperature of ≥ 38 °C, were bleeding, and had any other febrile symptoms were included. Previously confirmed VHF positive samples were used for assay verification. RESULTS: Overall, 7 pathogens were detected in 59 samples (32.42%) as follows: Plasmodium spp. (n = 49, 26.92%), non-typhoidal Salmonella (n = 3, 1.65%), Yellow Fever (YF) virus (n = 2, 1.10%), Salmonella enterica serovar typhi (n = 2, 1.10%), Leptospira spp (n = 1, 0.55%), Streptococcus pneumoniae (n = 1, 0.55%) and Rickettsia spp. (n = 1, 0.55%). Final outcome (alive vs. dead) as abstracted from case report forms differed significantly by pathogen category (p = 0.002) was significantly associated with assay positivity. We compared outcome across pathogen categories using a chi-square/Fisher's exact test, as appropriate, reporting p-values (Table 2). Cough was the only clinical symptom significantly associated with Plasmodium infection (p = 0.016). CONCLUSION: The TAC is a feasible, readily adoptable diagnostic tool for use in Uganda and other sub-Saharan countries, particularly when incorporated into the national testing algorithm for differential diagnosis during AFI outbreaks and surveillance. CLINICAL TRIAL NUMBER: Not applicable.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。